RS50165B - Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema - Google Patents

Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema

Info

Publication number
RS50165B
RS50165B YUP-290/02A YUP29002A RS50165B RS 50165 B RS50165 B RS 50165B YU P29002 A YUP29002 A YU P29002A RS 50165 B RS50165 B RS 50165B
Authority
RS
Serbia
Prior art keywords
emphysema
manufacture
treatment
medicaments
retinoid agonist
Prior art date
Application number
YUP-290/02A
Other languages
English (en)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
F. Hoffmann-La Roche Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag., filed Critical F. Hoffmann-La Roche Ag.,
Publication of YU29002A publication Critical patent/YU29002A/sh
Publication of RS50165B publication Critical patent/RS50165B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Primena RARγ selektivnih agonista za proizvodnju lekova koji sadrže jedan ili više takvih agonista za tretiranje emfizema. Prijava sadrži još 8 patentnih zahteva.
YUP-290/02A 1999-10-19 2000-10-13 Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema RS50165B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (2)

Publication Number Publication Date
YU29002A YU29002A (sh) 2005-06-10
RS50165B true RS50165B (sr) 2009-05-06

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-290/02A RS50165B (sr) 1999-10-19 2000-10-13 Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema

Country Status (34)

Country Link
US (1) US6300350B1 (sr)
EP (1) EP1225878B1 (sr)
JP (2) JP4074458B2 (sr)
KR (1) KR100485581B1 (sr)
CN (1) CN1201730C (sr)
AR (1) AR029648A1 (sr)
AT (1) ATE344661T1 (sr)
AU (1) AU777325B2 (sr)
BR (1) BR0015225A (sr)
CA (1) CA2387844C (sr)
CY (1) CY1105941T1 (sr)
CZ (1) CZ20021657A3 (sr)
DE (1) DE60031790T2 (sr)
DK (1) DK1225878T3 (sr)
ES (1) ES2274810T3 (sr)
HK (1) HK1051002A1 (sr)
HR (1) HRP20020329A2 (sr)
HU (1) HUP0203295A3 (sr)
IL (1) IL149151A0 (sr)
JO (1) JO2178B1 (sr)
MA (1) MA26835A1 (sr)
MX (1) MXPA02003843A (sr)
MY (1) MY129001A (sr)
NO (1) NO328738B1 (sr)
NZ (1) NZ518118A (sr)
PE (1) PE20010678A1 (sr)
PL (1) PL357499A1 (sr)
PT (1) PT1225878E (sr)
RS (1) RS50165B (sr)
RU (1) RU2257383C2 (sr)
TR (1) TR200201071T2 (sr)
TW (1) TWI288639B (sr)
WO (1) WO2001030326A1 (sr)
ZA (1) ZA200202576B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
EP1430024A1 (en) 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
BR0212607A (pt) 2001-09-18 2004-08-17 Hoffmann La Roche Agonistas retinóides ii de uréia substituìda
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
EP2089023A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with agonists of ppar-gamma
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
MX2015007797A (es) 2012-12-17 2015-10-05 Parion Sciences Inc Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
EP4083029A1 (en) 2013-08-20 2022-11-02 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
EP3039126B1 (en) 2013-08-26 2019-10-09 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) * 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
TR200001228T2 (tr) * 1997-11-12 2001-01-22 F.Hoffmann-La Roche Ag T yardımcı hücre tür 2 kökenli bağışıklık hastalıklarının retinoit antagonistlerle tedavisi
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
MXPA02000828A (es) * 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
NO20021823D0 (no) 2002-04-18
CN1382042A (zh) 2002-11-27
NO20021823L (no) 2002-04-18
PT1225878E (pt) 2007-01-31
KR100485581B1 (ko) 2005-04-27
HUP0203295A2 (hu) 2003-01-28
JP2007302689A (ja) 2007-11-22
CN1201730C (zh) 2005-05-18
KR20020043640A (ko) 2002-06-10
YU29002A (sh) 2005-06-10
AU777325B2 (en) 2004-10-14
HRP20020329A2 (en) 2004-04-30
AR029648A1 (es) 2003-07-10
ES2274810T3 (es) 2007-06-01
HK1051002A1 (en) 2003-07-18
TWI288639B (en) 2007-10-21
DE60031790D1 (de) 2006-12-21
CA2387844A1 (en) 2001-05-03
US6300350B1 (en) 2001-10-09
ZA200202576B (en) 2003-09-23
TR200201071T2 (tr) 2002-08-21
DE60031790T2 (de) 2007-09-20
AU1137401A (en) 2001-05-08
MXPA02003843A (es) 2002-09-30
PE20010678A1 (es) 2001-07-04
HUP0203295A3 (en) 2003-04-28
MA26835A1 (fr) 2004-12-20
DK1225878T3 (da) 2007-03-05
WO2001030326A1 (en) 2001-05-03
RU2257383C2 (ru) 2005-07-27
CY1105941T1 (el) 2011-04-06
EP1225878B1 (en) 2006-11-08
CZ20021657A3 (cs) 2002-10-16
NZ518118A (en) 2004-02-27
PL357499A1 (en) 2004-07-26
JP4074458B2 (ja) 2008-04-09
NO328738B1 (no) 2010-05-03
EP1225878A1 (en) 2002-07-31
JP4850791B2 (ja) 2012-01-11
JP2003512418A (ja) 2003-04-02
JO2178B1 (en) 2003-04-23
ATE344661T1 (de) 2006-11-15
IL149151A0 (en) 2002-11-10
MY129001A (en) 2007-03-30
BR0015225A (pt) 2002-07-16
CA2387844C (en) 2009-04-14

Similar Documents

Publication Publication Date Title
RS50165B (sr) Primena rar selektivnih retinoid antagonista za proizvodnju leka za tretiranje emfizema
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
SE0100901D0 (sv) New composition
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DZ2964A1 (fr) Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
NO303816B1 (no) Vandig retinoid-gelblanding
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
UY28348A1 (es) Compuestos novedosos
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO996208D0 (no) Nye 2-(iminometyl)amino- fenylderivater, fremstilling og blandinger derav, samt anvendelse som legemiddel
DK1056449T3 (da) 20-HETE-antagonister og -agonister
DK0929565T3 (da) Nitratestere af corticoidforbindelser og farmaceutiske anvendelser deraf
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
CY1107158T1 (el) Νεα παραγωγα της ισοκινολινης, η μεθοδος παρασκευης τους και η χρηση τους για τη θεραπεια των διαταραχων του μελατονινεργικου συστηματος
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
RS51534B (sr) Novi spoj inihbitora sinusoidne if struje i kalcijumskog inhibitora i farmaceutske smeše koje ga sadrže
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona